Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
US-2024425923-A1 · Dec 26, 2024 · US
RGS2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US8986929B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8986929-B2 |
| Application number | US-201113155199-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 7, 2011 |
| Priority date | Jun 12, 2006 |
| Publication date | Mar 24, 2015 |
| Grant date | Mar 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for identifying a human subject as having a decreased tendency to develop Parkinsonism as an extrapyramidal symptom following treatment with an antipsychotic drug, said method comprising: obtaining a sample comprising genetic material of said subject; detecting, in said genetic material, the presence of at least one allele of the regulator of G-protein signaling 2 gene, comprising guanine at the SNP rs4606 thereby identifying the human subje…
Assignees
Inventors
Classifications
- C12Q1/6883Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8986929B2 cover?
- The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates t…
- Who is the assignee on this patent?
- Lerer Bernard, Greenbaum Lior, Hadasit Med Res Service
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6883. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).